AU2021214939A1 - Compositions and methods for treating and preventing hepatitis B and D - Google Patents

Compositions and methods for treating and preventing hepatitis B and D Download PDF

Info

Publication number
AU2021214939A1
AU2021214939A1 AU2021214939A AU2021214939A AU2021214939A1 AU 2021214939 A1 AU2021214939 A1 AU 2021214939A1 AU 2021214939 A AU2021214939 A AU 2021214939A AU 2021214939 A AU2021214939 A AU 2021214939A AU 2021214939 A1 AU2021214939 A1 AU 2021214939A1
Authority
AU
Australia
Prior art keywords
nucleic acid
hepatitis
seq
immunogenic composition
product combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021214939A
Other languages
English (en)
Inventor
Lars Frelin
Matti SÄLLBERG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Svenska Vaccinfabriken Produktion AB
Original Assignee
Svenska Vaccinfabriken Produktion AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Svenska Vaccinfabriken Produktion AB filed Critical Svenska Vaccinfabriken Produktion AB
Publication of AU2021214939A1 publication Critical patent/AU2021214939A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10111—Deltavirus, e.g. hepatitis delta virus
    • C12N2760/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Beans For Foods Or Fodder (AREA)
AU2021214939A 2020-01-28 2021-01-26 Compositions and methods for treating and preventing hepatitis B and D Pending AU2021214939A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062966970P 2020-01-28 2020-01-28
US62/966,970 2020-01-28
PCT/US2021/015126 WO2021154752A1 (en) 2020-01-28 2021-01-26 Compositions and methods for treating and preventing hepatitis b and d

Publications (1)

Publication Number Publication Date
AU2021214939A1 true AU2021214939A1 (en) 2022-09-15

Family

ID=74673345

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021214939A Pending AU2021214939A1 (en) 2020-01-28 2021-01-26 Compositions and methods for treating and preventing hepatitis B and D

Country Status (9)

Country Link
US (1) US20230079898A1 (cg-RX-API-DMAC7.html)
EP (1) EP4096711A1 (cg-RX-API-DMAC7.html)
JP (1) JP7855515B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220149519A (cg-RX-API-DMAC7.html)
CN (1) CN115335075A (cg-RX-API-DMAC7.html)
AU (1) AU2021214939A1 (cg-RX-API-DMAC7.html)
CA (1) CA3169407A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022009169A (cg-RX-API-DMAC7.html)
WO (1) WO2021154752A1 (cg-RX-API-DMAC7.html)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101564533B (zh) * 2009-06-12 2012-01-04 东南大学 戊型肝炎蛋白-核酸复合疫苗及其制备方法
CN102895659B (zh) * 2011-07-29 2014-10-29 复旦大学 一种防治老年痴呆症复合疫苗及其制备方法
US10905760B2 (en) 2016-01-28 2021-02-02 Svenska Vaccinfabriken Produktion Ab Chimeric hepatitis D virus antigen and hepatitis B virus pre S1 genes for use alone or in vaccines containing hepatitis B virus genes
AU2017332854B2 (en) * 2016-09-21 2024-11-14 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof

Also Published As

Publication number Publication date
JP7855515B2 (ja) 2026-05-08
KR20220149519A (ko) 2022-11-08
CN115335075A (zh) 2022-11-11
JP2023512526A (ja) 2023-03-27
CA3169407A1 (en) 2021-08-05
EP4096711A1 (en) 2022-12-07
US20230079898A1 (en) 2023-03-16
WO2021154752A1 (en) 2021-08-05
MX2022009169A (es) 2022-12-08

Similar Documents

Publication Publication Date Title
US11478544B2 (en) Chimeric hepatitis D virus antigen and hepatitis B virus pre S1 genes for use alone or in vaccines contaning hepatitis B virus genes
EP2391383B1 (en) Codon-optimized hepatitis b virus core antigen (hbcag)
US20230330211A1 (en) Compositions and methods for treating and preventing coronaviruses
WO2012141280A1 (ja) Dnaワクチン
US20230079898A1 (en) Compositions and methods for treating and preventing hepatitis b and d
US20250197452A1 (en) Compositions and methods for treating and preventing hepatitis b and d
RU2812764C1 (ru) Композиции и способы для лечения и предотвращения гепатита в и d
ES2985391T3 (es) Métodos y composiciones para el tratamiento de la infección por hepatitis B
HK40083708A (en) Compositions and methods for treating and preventing hepatitis b and d
US20240382584A1 (en) Hbv vaccine inducing pres-specific neutralizing antibodies
WO2025226656A1 (en) Hepatitis b virus mrna vaccines
WO2024186780A2 (en) Compositions and methods for treating and preventing crimean congo hemorrhagic fever virus
WO2025080857A1 (en) Compositions and methods for treating and preventing hepatitis a and e
AU2004281098A1 (en) Pharmaceutical compositions for therapeutic use
GB2440528A (en) Antigen-antibody complexes
US20120027795A1 (en) Simple vaccines from dna launched suicidal flaviviruses
HK1165694B (en) Codon-optimized hepatitis b virus core antigen (hbcag)